Pfizer Building Viagra As Pan-European Consumer Health Brand With Rx-To-OTC Switch In Norway
Executive Summary
Pfizer has taken the first steps towards turning its Viagra erectile dysfunction treatment into a pan-European OTC brand by taking advantage of Norway's new "non-prescription medicines with guidance" category to secure the Rx-to-OTC switch of the product. Norway will be the second European market where Viagra is available OTC after the UK switched the drug in 2017.
You may also be interested in...
Why Did Germany Reject Sildenafil OTC Switch?
Sildenafil was rejected at Germany’s independent switch committee’s most recent meeting. HBW Insight examines some of the arguments for and against the switch put forward by the regulator, members of the committee and the applicant, as recorded in the recently published minutes.
Poland’s Adamed Secures Tadalafil Rx-To-OTC Switch In World First
Poland becomes the first country in the world to allow erectile dysfunction treatment tadalafil to be bought without a prescription thanks to a successful Rx-to-OTC switch application from local player Adamed Pharma.
OTCs' Rapid Remedies Should Mitigate Weight Of Self-Selection Risks For Switches – Consultant
OTC drugs’ quick treatment of acute conditions outweighs risks from absence of physician oversight, says OTC switch consultant Bernie Simone. At CHPA regulatory conference, he discussed other drug categories during his presentation on the downside of keeping some drug ingredients Rx-only.